针对NLRP3炎症体-气体皮质D轴,对抗心血管疾病
Judy S Choi1, Mehnaz Pervin2, James E Vince3
1Cardiovascular Inflammation and Redox Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; Department of Immunology and Pathology, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.
Journal of molecular and cellular cardiology
|September 25, 2025
概括
炎症驱动心血管疾病通过NLRP3炎症酶激活和气体皮质D介导的活化. 针对这一轴为动脉样硬化和心肌梗塞等疾病提供了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 分子生物学分子生物学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 炎症是心血管疾病病理学的关键驱动因素.
- 目前的心血管疾病治疗往往控制症状,而不是潜在的机制.
研究的目的:
- 审查NLRP3炎症酶激活和气体皮质D介导的Pyroptosis在心血管疾病中的作用.
- 突出针对NLRP3炎症体-气皮质D轴的治疗策略.
主要方法:
- 临床前和临床研究的文献综述.
- 专注于在心血管疾病中炎症酶激活和热的分子机制.
- 对新兴治疗点的分析.
主要成果:
- NLRP3炎症酶激活导致气体皮质D介导的热,导致心血管疾病.
- 这一途径与动脉样硬化,心肌梗塞,缺血性中风和糖尿病心肌病相关.
- 针对NLRP3炎症体-气皮D轴的向显示出治疗的前景.
结论:
- NLRP3炎症体-气体皮质D通路是心血管炎症和损伤的关键调解者.
- 该轴的抑制代表了各种心血管疾病的有希望的治疗途径.
- 需要进一步的研究和临床试验来验证这些新的治疗方法.
相关概念视频
Rheumatic Heart Disease III: Medical Management
289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289
Inflammation
61.7K
Overview
61.7K
Peripheral Artery Disease III: Interprofessional Care
245
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
245
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Antianginal Drugs: Nitrates and β-Blockers
1.4K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.4K


